Sansure Biotech(SH:688289)2024-10-23 10:41Financial Performance - The company's operating revenue for Q3 2024 reached ¥315,623,085.49, representing a year-on-year increase of 54.08%[2] - The net profit attributable to shareholders for Q3 2024 was ¥38,721,202.19, showing a significant decrease of 81.39% compared to the same period last year[2] - The basic earnings per share for Q3 2024 was ¥0.07, down 80.00% from the same period last year[3] - The company reported a significant increase in net profit attributable to shareholders after excluding non-recurring gains and losses, which rose by 637.21% year-to-date[6] - Net profit for the third quarter of 2024 was ¥163,076,994.01, a decrease of 45.4% from ¥298,485,079.76 in the same quarter of 2023[15] - The total comprehensive income attributable to the parent company was CNY 185,983,821.75, down from CNY 291,899,926.18 in the previous year, representing a decrease of approximately 36.2%[16] - The company reported a basic earnings per share of CNY 0.34, down from CNY 0.51 year-over-year, reflecting a decline of approximately 33.3%[16] Cash Flow and Liquidity - The net cash flow from operating activities for Q3 2024 was ¥52,825,121.07, a notable improvement from a negative cash flow of ¥9,978,864.61 in the previous year[2] - The net cash flow from operating activities was negative CNY 9,978,864.61, an improvement from negative CNY 169,579,893.12 in the same period last year[18] - The company incurred cash outflows from operating activities totaling CNY 1,314,462,196.71, down from CNY 1,519,821,792.74, a reduction of about 13.5%[18] - The net increase in cash and cash equivalents for the period was CNY 163,721,549.58, compared to CNY 327,047,757.31 in the previous year, reflecting a decrease of approximately 50%[19] - The total cash and cash equivalents at the end of the period increased to CNY 4,335,335,961.46 from CNY 3,426,097,883.74, marking an increase of about 26.5%[19] - The company reported a total cash inflow from financing activities of CNY 429,581,858.96, with a net cash flow from financing activities of CNY 149,286,849.93, compared to a net outflow in the previous year[19] Assets and Liabilities - The total assets of the company at the end of Q3 2024 amounted to ¥8,571,194,405.07, reflecting a 1.38% increase from the end of the previous year[3] - The company's total assets increased to ¥8,571,194,405.07 in Q3 2024, compared to ¥8,454,204,974.00 in Q3 2023, marking a growth of 1.4%[12] - Total liabilities rose to ¥1,218,127,146.43 in Q3 2024, up from ¥1,029,297,739.69 in Q3 2023, indicating an increase of 18.3%[12] - The total equity attributable to shareholders at the end of Q3 2024 was ¥7,238,107,810.77, a slight increase of 0.51% from the previous year[3] - The total equity attributable to shareholders reached ¥7,238,107,810.77 in Q3 2024, compared to ¥7,201,271,019.35 in Q3 2023, showing a slight increase of 0.5%[12] Research and Development - Research and development expenses totaled ¥91,060,774.48 in Q3 2024, an increase of 58.56% year-on-year, accounting for 28.85% of operating revenue[3] - Research and development expenses for the third quarter of 2024 were ¥189,915,613.99, compared to ¥137,493,724.89 in the same quarter of 2023, reflecting a growth of 38.2%[15] - The development expenditure for new technologies reached CNY 85,157,146.77, up from CNY 44,684,836.34, indicating an increase of about 90.5% year-over-year[10] Inventory and Receivables - The company's accounts receivable decreased to CNY 608,556,426.98 from CNY 689,547,683.46, reflecting a decline of approximately 11.5% year-over-year[10] - Inventory increased to CNY 419,030,490.79, up from CNY 376,632,763.99, indicating a growth of about 11.2% compared to the previous year[10] - The total current assets decreased to CNY 5,742,694,872.97 from CNY 5,949,593,915.93, representing a decline of approximately 3.5% year-over-year[10] Government Support and Strategy - The company received government subsidies amounting to ¥12,994,732.67 in Q3 2024, contributing positively to its financial performance[4] - The company has implemented an innovation-driven strategy, leading to substantial growth in key areas such as respiratory, maternal and child health, blood source, and sequencing technologies[6] - The company has not disclosed any new strategies or market expansions during this reporting period[9]